WilmerHale represented the underwriters in the public offering of 7,344,543 shares of common stock and 23,126 shares of Series B non-voting convertible preferred stock of Viridian Therapeutics, Inc., a biopharmaceutical company, at a public offering price of $11.00 per share of common stock and $733.37 per share of Series B non-voting convertible preferred stock. The shares of common stock sold reflected the full exercise of the underwriters’ option to purchase additional shares, and the gross proceeds to the company were approximately $97.7 million, before deducting underwriting discounts and offering expenses. The offering priced on September 20, 2021 and closed on September 23, 2021.

The WilmerHale team advising the underwriters consisted of Lisa Firenze, Molly Fox, Benn Waters and Gerard Fischetti, with assistance from Bruce Manheim, Colleen Superko and Heidi Treiber.

For more information, read Viridian’s press release.